Frankfurt
15.04.26 | 15:25
4,480 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | INVENTIVA: Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F | 516 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 8, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 08.04. | Inventiva S.A. - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 07.04. | Piper Sandler reiterates Inventiva stock rating ahead of trial | 5 | Investing.com | ||
| 31.03. | MASH-Studie: Leerink bekräftigt positive Einschätzung für Inventiva | 5 | Investing.com Deutsch | ||
| 31.03. | Leerink reiterates Inventiva stock rating on MASH trial progress | 1 | Investing.com | ||
| 31.03. | Stifel cuts Inventiva stock price target on dilution concerns | 3 | Investing.com | ||
| 30.03. | INVENTIVA: Inventiva reports 2025 full year results and provides a business update | 1.263 | GlobeNewswire (Europe) | Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering... ► Artikel lesen | |
| 23.03. | INVENTIVA: Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results | 540 | GlobeNewswire (Europe) | Daix (France), New York (United States), March 23, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 18.03. | Truist initiates Inventiva stock with buy on MASH therapy potential | 5 | Investing.com | ||
| 03.03. | Danaher, Moderna, Emyria: Drei Biotech-Aktien für die Beobachtungsliste im März 2026 | Small- & Micro Cap Investment | |||
| 26.02. | INVENTIVA: Inventiva to Participate in Four Upcoming March Investor Conferences | 437 | GlobeNewswire (Europe) | Daix (France), New York (United States), February 26, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 17.02. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.02. | INVENTIVA: Inventiva reports preliminary 2025 fiscal year financial results | 579 | GlobeNewswire (Europe) | Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds... ► Artikel lesen | |
| 04.02. | INVENTIVA: Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | 347 | GlobeNewswire (Europe) | Daix (France), New York (United States), February 4, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 28.01. | H.C. Wainwright reiterates Buy rating on Inventiva stock at $24 price target | 4 | Investing.com | ||
| 26.01. | INVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux | 837 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), January 26, 2026 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 12.01. | Leerink Partners initiates coverage on Inventiva stock with Outperform rating | 12 | Investing.com | ||
| 07.01. | UBS startet Coverage für Inventiva mit Kaufempfehlung und 12-Dollar-Kursziel | 14 | Investing.com Deutsch | ||
| 07.01. | UBS assumes coverage on Inventiva stock with Buy rating, $12 target | 19 | Investing.com | ||
| 17.12.25 | INVENTIVA: Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference | 469 | GlobeNewswire (Europe) | Daix) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH")... ► Artikel lesen |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 12,200 | -1,61 % | EyePoint, Inc. - 8-K, Current Report | ||
| EDWARDS LIFESCIENCES | 66,08 | -0,12 % | Edwards Lifesciences Corp. Q4 Profit Falls | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) announced earnings for fourth quarter that Drops, from last yearThe company's earnings totaled $91.2 million, or $0.16 per share. This... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,296 | +0,31 % | Organigram Global Inc.: Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 24,550 | -2,58 % | Assembly Biosciences vor ESCMID-Auftritt: Ab ins Rampenlicht | Mein Biotech-Favorit Assembly Biosciences rückt zunehmend in den Fokus der internationalen Wissenschafts- und Investorengemeinde. Das Unternehmen kündigte an, mehrere Datensätze aus jüngsten Proof-of-Concept-Studien... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,965 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces Release Date for Year End 2025 and Q1 2026 Financial Results | Toronto, Ontario--(Newsfile Corp. - April 15, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 155,15 | -0,26 % | UBS raises Axsome Therapeutics price target on Auvelity outlook | ||
| COMPASS PATHWAYS | 4,980 | -2,35 % | Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based organizations... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,860 | -4,67 % | Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions | Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027... ► Artikel lesen | |
| ALTIMMUNE | 2,885 | +0,35 % | Altimmune, Inc: Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 169,65 | +0,41 % | Prognose massiv erhöht - Wird der australische Psychodelika-Spezialist Bioxyne zum neuen Branchenliebling? | ||
| SELLAS LIFE SCIENCES | 4,130 | -0,48 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| DAIICHI SANKYO | 15,282 | -2,91 % | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,776 | -4,52 % | XORTX Therapeutics Inc.: XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset | • VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results | Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA (gepirone) extended-release... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 26,290 | -3,20 % | Rigel Pharmaceuticals-Aktie: Klarer Kaufkandidat nach Rücksetzer | Die Aktie des Biotechunternehmens Rigel Pharmaceuticals steht derzeit im Zeichen eines deutlichen Umsatzanstiegs und wachsender operativer Stabilität. Gleichzeitig richtet sich der Blick der Investoren... ► Artikel lesen |
INVENTIVA SA ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,480 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.